Table 1.

Clinical characteristics and mutation status of family members.

Family Member	Age at Examination	Diabetes	BMI	Age at Diabetes Diagnosis	Duration of Diabetes	Diabetes Treatment	Albumin: Creatinine Ratio (μg/mg)	ESRD	Hypo-adiponectinemia	Hyper-ceramidemia	HLA Statusc	ADIPOQ Mutation Status
II:4	>60	Yes	40.1	<40	51	Oral	34.2	No	No	Yes	X/X	WT
III:2	>60	No	24.6	–	–	–	14.8	No	Yes	Yes	X/X	MUT
III:3	>60	Yes	27.3	>60a	–	Unknown	6.7	No	Yes	Yes	X/X	MUT
III:4	>60	Yes	25.6	<40	32	Oral	>2500	Yes	Yes	Yes	X/X	MUT
III:5	>60	Yes	29.2	<40	44	Insulin	313.3	Yesb	Yes	Yes	X/X	MUT
III:7	>60	Yes	31.2	40–60	13	Oral	>2500	Yes	Yes	No	X/X	MUT
III:8	40–60	Yes	31.4	40–60a	0	Diet	28.3	No	Yes	Yes	DR4/X	MUT
III:9	>60	Yes	33.2	<40	35	Insulin	22.4	Yesb	Yes	Yes	DR4/X	MUT
IV:1	40–60	No	35.5	–	–	–	2.6	No	Yes	Yes	X/X	MUT
IV:2	<40	Yes	36.7	<40a	0	Diet	39.3	No	No	No	DR3/4	WT
IV:3	40–60	Yes	34.5	<40	25	Insulin	219.9	Yesb	Yes	Yes	X/X	MUT
IV:4	<40	Yes	31.3	<40	16	Insulin	325.6	Yesb	Yes	Yes	DR3/X	MUT
V:1	<40	Yes	37.8	<40a	0	Oral	16.2	No	No	No	DR4/X	WT
V:2	<40	Yes	26.9	<40a	1	Insulin	5.9	No	No	No	DR4/X	WT

Data are from baseline clinical characteristics collected at time of enrollment to the Joslin Study on the Genetics of Type 2 Diabetes except as noted. ADIPOQ mutation non-carriers (WT); ADIPOQ mutation carriers (MUT).

^aThese family members had a diagnosis of diabetes either shortly before enrollment to the Joslin Study on the Genetics of Type 2 Diabetes (III:8) or following their participation in this study (III:3, IV:2, V:1, V:2).

^bThese family members had either normoalbuminuria (III:9) or proteinuria (III:5, IV:3, and IV:4) at enrollment to the Joslin Study on the Genetics of Type 2 Diabetes and later progressed to end-stage renal disease (ESRD).

^cHuman leukocyte antigen (HLA) alleles DR3 (haplotype DQA1*05:01-DQB1*02:01) and DR4 (haplotype DQA1*03-DQB1*03:02) are indicated, X is neither DR3 or DR4.